3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
94
Leukemia, Lymphocytic, Chronic, B-Cell
56
Neoplasms
37
Recurrence
28
Lymphoma, Non-Hodgkin
25
Myelodysplastic Syndromes
21
Multiple Myeloma
18
Leukemia
16
Lymphoma, Large B-Cell, Diffuse
11
Leukemia, Myelomonocytic, Chronic
10
Hematologic Neoplasms
10
Lymphoma, Mantle-Cell
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Follicular
7
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myeloid
6
Lymphoma
5
Chromosome 17 deletion
5
Lymphoma, B-Cell
4
Breast Neoplasms
4
Waldenstrom Macroglobulinemia
3
Small Cell Lung Carcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Neuroblastoma
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoproliferative Disorders
2
Hematologic Diseases
2
GATA2 Deficiency
2
Interventions
ofatumumab
10
ibrutinib
6
Rituximab
5
acalabrutinib
4
Cyclophosphamide
3
spebrutinib
2
pirtobrutinib
2
obinutuzumab
2
navitoclax
2
fludarabine phosphate
2
Tablets
2
Lenalidomide
2
KW-2478
2
Chlorambucil
2
Antigens, CD19
2
ARQ531
2
venetoclax
1
tirabrutinib
1
pomalidomide
1
pivalyloxymethyl butyrate
1
immunotoxin HA22
1
idelalisib
1
idecabtagene vicleucel
1
fludarabine
1
dinaciclib
1
bempegaldesleukin
1
Vincristine
1
Rabeprazole
1
Prednisone
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, B-Cell
×
venetoclax
×
Clear all
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA